Maternal Antibodies Key to Protecting Newborns from Deadly E. Coli Infections, Study Finds
New research published March 11, 2026, in the journal Nature, reveals a critical link between maternal antibodies and protection against severe Escherichia coli (E. Coli) infections in newborns. The multi-center study, led by researchers at Cincinnati Children’s, found that babies who develop E. Coli sepsis have significantly reduced levels of germ-fighting antibodies transferred from their mothers.
Why are Some Newborns More Susceptible to E. Coli?
E. Coli is a common bacterium residing in the intestines of most people, but it’s also a leading cause of severe infection in newborns. Despite widespread exposure to E. Coli shortly after birth, severe infection occurs in only about one in every 1,000 live births 1. This disparity prompted researchers to investigate why some infants are more vulnerable than others.
The Role of Maternal Antibodies
The study revealed that babies who became severely ill from E. Coli infections had markedly lower levels of antibodies transferred from their mothers. These antibodies, stimulated by the presence of E. Coli in the mother’s gut, are crucial for protecting against infection. “This helps explain a long-standing question: if most babies are exposed to germs soon after birth, why don’t even more develop severe infection?” says senior author Sing Sing Way, MD, PhD, of Cincinnati Children’s 2.
How the Study Was Conducted
Researchers collaborated across multiple institutions, including Cincinnati Children’s, the University of Queensland in Australia, University of Texas Southwestern Medical Center, Children’s Mercy Kansas City and the University of Missouri Kansas City School of Medicine. They analyzed dried blood samples collected for routine newborn screening from 100 babies who later developed E. Coli infection, comparing their antibody levels to those of uninfected infants. The analysis consistently showed reduced antibodies targeting E. Coli in infected babies 4.
Probiotic Potential for Enhanced Protection
Further research using mice demonstrated that introducing a probiotic strain of E. Coli, Nissle 1917 (EcN), to mothers before pregnancy stimulated the production of protective antibodies. These antibodies effectively protected newborn mice against infection. EcN is available for human use in Europe, Asia, and Australia under the trade name Mutaflor 1.
Future Directions: Screening and Prevention
Researchers are now focused on developing a screening test to identify newborns at highest risk of severe E. Coli infection and exploring the potential of a safe probiotic for mothers to strengthen their immunity and transfer more protective antibodies to their babies. “Neonatal sepsis can escalate quickly, and clinicians demand better ways to identify which infants are at highest risk,” says Susana Chavez-Bueno, MD, of Children’s Mercy Hospital in Kansas City 3.
Key Takeaways
- Newborns are vulnerable to E. Coli infection, but most are protected by antibodies received from their mothers.
- Babies who develop severe E. Coli sepsis have lower levels of these protective maternal antibodies.
- A probiotic strain, E. Coli Nissle 1917, shows promise in boosting maternal antibody production and protecting newborns.
- Future research aims to develop screening tests and preventative strategies to reduce the risk of E. Coli infection in newborns.